PRIORIX DIN 02239208
Status: Marketed
Holder: GLAXOSMITHKLINE INC
Available to quote
Health Canada record
| Active ingredient(s) | MEASLES VIRUS LIVE ATTENUATED (SCHWARZ STRAIN) 1000 CCID50; MUMPS VIRUS LIVE ATTENUATED (RIT 4385 STRAIN) 5011.8723 CCID50; RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA27/3 STRAIN) 1000 CCID50 |
|---|---|
| Dosage form | Powder For Solution; Kit |
| Route | Subcutaneous; Intramuscular |
| Schedule | SCHEDULE D |
| Class | Human |
| ATC | J07BD52 MEASLES, COMBIN. WITH MUMPS AND RUBELLA, LIVE ATTENUATED |
| Original market date | 04-Dec-1998 |
| Current status date | 23-Feb-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MEASLES VIRUS LIVE ATTENUATED (SCHWARZ STRAIN)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02297884 | PRIORIX-TETRA | GLAXOSMITHKLINE INC | Powder For Solution | MEASLES VIRUS LIVE ATTENUATED (SCHWARZ STRAIN) 1000 CCID50; MUMPS VIRUS LIVE ATTENUATED (RIT 4385 STRAIN) 25118.9 CCID50; RUBELLA VIRUS LIVE ATTENUATED (WISTAR RA27/3 STRAIN) 1000 CCID50; VARICELLA-ZOSTER VIRUS LIVE ATTENUATED (OKA-STRAIN) 1995.2623 PFU | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 2408 | 2001-10-12 | New Drug Submission (NDS) | CHANGE IN MANUFACTURER NAME |
| 3037 | 1998-12-04 | New Drug Submission (NDS) |